

Supplementary Table 1. Baseline characteristics according to reaching target glycemic state (HbA1c \leq 7.0%) at 24-week

Characteristic	No reach target glycemic control (HbA1c >7.0%)	Reach target glycemic control (HbA1c \leq 7.0%)	<i>P</i> value
Number	23 (24.0)	73 (76)	
Age, yr	59 \pm 11	51 \pm 11	0.01
Male sex	46 (63.0)	12 (52.2)	0.50
Diabetes duration, yr	10 (6–16)	8 (5–14.5)	0.35
BMI, kg/m ²	25.4 (24.2–27.8)	27.6 (26.1–30.1)	0.02
SBP, mm Hg	128 \pm 17	124 \pm 16	0.34
DBP, mm Hg	75 \pm 12	75 \pm 14	0.77
Laboratory findings			
Glucose, mg/dL	163 (127–202)	155 (116–191)	0.30
HbA1c, %	9.1 \pm 1.0	8.8 \pm 1.0	0.22
C-peptide, ng/mL	1.7 (1.2–2.3)	2.1 (1.3–2.6)	0.21
Total cholesterol, mg/dL	148 \pm 42	156 \pm 32	0.38
Triglyceride, mg/dL	164 (104–238)	186 (135–253)	0.44
HDL-cholesterol, mg/dL	46 \pm 10	44 \pm 8	0.34
LDL-cholesterol, mg/dL	88 \pm 33	96 \pm 25	0.27
Uric acid, mg/dL	4.9 \pm 1.4	5.3 \pm 1.9	0.33
AST, U/L	27 \pm 13	32 \pm 16	0.16
ALT, U/L	31 \pm 19	36 \pm 23	0.28
Creatinine, mg/dL	0.8 (0.6–0.9)	0.8 (0.7–0.9)	0.87
uACR, mg/g	21.3 (10.6–81.2)	29.5 (13.9–100)	0.37
eGFR, mL/kg/m ²	99.6 \pm 23.0	95.6 \pm 26.0	0.48
Combination of triple therapy at baseline			
Metformin (dose), mg/day	2,000 (1,500–2,000)	1,700 (1,000–2,000)	0.06
Sulfonylurea (dose), mg/day	6 (4–8)	4 (2–7)	0.09
DPP-4i (yes)	45 (61.6)	19 (82.6)	0.11
TZD (yes)	3 (4.1)	2 (8.7)	0.75
SGLT2 inhibitors (yes)	25 (34.2)	3 (13.0)	0.09

Values are presented as number (%), mean \pm standard deviation, or median (interquartile ranges).

HbA1c, glycosylated hemoglobin; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine transferase; uACR, urine albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; DPP-4i, dipeptidyl peptidase-4; TZD, thiazolidinedione, SGLT2, sodium-glucose co-transporter 2.